Has Michael Sweeney, MD received payments from drug or device companies?

Yes. Drug and device makers reported $71,168 in general payments to Michael Sweeney, MD across 147 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael Sweeney, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael Sweeney, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael Sweeney, MD

Neurology · Louisville, KYNPI 1235455494

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $50,825 of the $71,168 with a category attached, or 71.4%. Genentech USA, Inc. accounts for 86.9% of it on its own, with 18 other manufacturers making up the rest. Among neurology clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$71,168in general payments, 2019–2025

Across 147 payments — averaging $484.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Genentech USA, Inc.$62K
Novartis$5K
Roche Products Limited$1K
Smith+Nephew$684
Intuitive Surgical$563
AstraZeneca$350
plus $925 from 13 others

$135,672in research payments, 2019–2025

Across 8 payments — averaging $16,959 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$136K

What the payments were for

Consulting fees$6,4109%
Speaking & faculty fees$50,82571%
Travel & lodging$9,16513%
Food & beverage$4,4186%
Education$3500%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Genentech USA, Inc.	55	$61,824
Novartis	17	$5,409
Roche Products Limited	4	$1,414
Smith+Nephew	41	$684
Intuitive Surgical	3	$563
AstraZeneca	4	$350
E.r. Squibb & Sons, L.L.C.	2	$211
TG Therapeutics, Inc.	2	$156
Biogen	1	$150
Livanova USA, Inc.	5	$95
UCB, Inc.	4	$70
Boston Scientific	1	$55
Genentech, Inc.	1	$49
Johnson & Johnson(2 entities)	2	$41
Mallinckrodt Enterprises LLC	1	$23
Aquestive Therapeutics, Inc.	1	$19
Eisai Inc.	1	$19
Bristol Myers Squibb	1	$18
PTC Therapeutics, Inc.	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$71,168 in reported general payments places this provider in the 90th percentile of 210 neurology providers in Kentucky.

See all neurology providers in Kentucky →

Medicare billing

Part B allowed, 2024

$3,053

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
GammakedImmune Globul G/Gly/Iga Avg 46	13	$301,294
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50	13	$232,477
HizentraImmun Glob G(Igg)/Pro/Iga 0-50	13	$172,146
CopaxoneGlatiramer Acetate	19	$106,014
Dimethyl Fumarate	12	$53,927
Teriflunomide	11	$48,364
Glatiramer Acetate	15	$40,463
Aimovig AutoinjectorErenumab-Aooe	12	$8,989
Methylphenidate ErMethylphenidate Hcl	11	$4,291
Modafinil	37	$1,875
Gabapentin	135	$1,795
Mycophenolate Mofetil	20	$1,710
Baclofen	87	$1,519
Carbamazepine	12	$1,023
Phenobarbital	15	$421

Paid to pharmacies, not to this prescriber.

Other neurology in Louisville

Brian PlatoLouisville$232K
Kristi NordLouisville$217K
Angela HardwickLouisville$187K
Peter HederaLouisville$185K
Jeffrey FrankLouisville$181K
Mohammad AlsorogiLouisville$111K
Tad SeifertLouisville$99K
Michael SowellLouisville$60K
David RobertsonLouisville$58K
Jenny FengLouisville$47K

See the full list for Kentucky →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →